• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effect of optimal lesion preparation prior to implantation of a magnesium-based bioresorbable scaffold: 12-month results of the OPTIMIS study.

作者信息

Hansen Kirstine Nørregaard, Maehara Akiko, Trøan Jens, Noori Manijeh, Hougaard Mikkel, Ellert Julia, Veien Karsten Tange, Junker Anders, Hansen Henrik Steen, Lassen Jens Flensted, Jensen Lisette Okkels

机构信息

Department of Cardiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.

Cardiovasc.lar Research Foundation, New York Presbyterian Hospital, New York, USA.

出版信息

Cardiovasc Revasc Med. 2025 Aug;77:45-53. doi: 10.1016/j.carrev.2025.03.003. Epub 2025 Mar 5.

DOI:10.1016/j.carrev.2025.03.003
PMID:40074646
Abstract

BACKGROUND

Lumen reduction after bioresorbable scaffold implantation has been reported. This study aimed to assess the influence of pre-dilatation with a scoring balloon versus a standard non-compliant balloon prior to implanting a magnesium-based Magmaris bioresorbable scaffold (MgBRS) on lumen measurements using optical coherence tomography (OCT) and on clinical outcomes after 12 months.

METHOD

In the OPTIMIS-study (Optimal lesion preparation before implantation of a MgBRS in patients with coronary artery stenosis), patients were randomly assigned to pre-dilatation with a scoring balloon or a standard non-compliant balloon before MgBRS implantation. OCT was performed before and after scaffold implantation, and at 6- and 12-month follow-up. Clinical 12-month follow-up was performed for all 82 enrolled patients.

RESULTS

Serial pre- and post-procedural, 6- and 12-month OCT were available in 33 lesions (scoring: n = 16 vs. standard: n = 17). Minimal lumen area (MLA) (scoring 4.6 ± 0.5 mm vs. standard 3.6 ± 0.5 mm, p = 0.16) did not differ significantly at 12 months. In both the scoring and standard non-compliant balloon group, MLA changed significantly over time (post-procedure - 6-month - 12-month) (scoring balloon: 7.2 ± 1.8 mm-5.1 ± 1.7 mm-5.0 ± 1.9 mm, p < 0.01, and standard non-compliant balloon: 6.2 ± 1.1 mm-5.2 ± 1.5 mm-5.3 ± 2.0 mm, p < 0.01). No target lesion revascularizations (TLR) occurred in the scoring balloon group, compared to 7 TLR in the standard non-compliant balloon group within 12 months.

CONCLUSION

In lesions treated with MgBRS, MLA did not differ significantly after 12 months among lesions pre-dilated with a scoring balloon compared to a standard non-compliant balloon. However, only lesions pre-dilated with a scoring balloon were free from TLR.

摘要

相似文献

1
Effect of optimal lesion preparation prior to implantation of a magnesium-based bioresorbable scaffold: 12-month results of the OPTIMIS study.
Cardiovasc Revasc Med. 2025 Aug;77:45-53. doi: 10.1016/j.carrev.2025.03.003. Epub 2025 Mar 5.
2
Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis: The OPTIMIS Trial.冠状动脉狭窄患者植入Magmaris生物可吸收支架前的最佳预扩张治疗:OPTIMIS试验
Circ Cardiovasc Interv. 2025 Jan;18(1):e014665. doi: 10.1161/CIRCINTERVENTIONS.124.014665. Epub 2025 Jan 21.
3
Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.第二代药物洗脱可吸收金属支架在初发冠状动脉病变患者中的安全性和性能(BIOSOLVE-II):前瞻性、多中心、非随机、首例人体试验的 6 个月结果。
Lancet. 2016 Jan 2;387(10013):31-9. doi: 10.1016/S0140-6736(15)00447-X. Epub 2015 Oct 12.
4
Optimal lesion preparation before implantation of a Magmaris bioresorbable scaffold in patients with coronary artery stenosis: Rationale, design and methodology of the OPTIMIS study.冠状动脉狭窄患者植入Magmaris生物可吸收支架前的最佳病变准备:OPTIMIS研究的原理、设计与方法
Contemp Clin Trials Commun. 2024 Feb 7;38:101260. doi: 10.1016/j.conctc.2024.101260. eCollection 2024 Apr.
5
Mg-Zn-Ca Alloy (ZX00) Screws Are Resorbed at a Mean of 2.5 Years After Medial Malleolar Fracture Fixation: Follow-up of a First-in-humans Application and Insights From a Sheep Model.镁锌钙合金(ZX00)螺钉在用于固定内踝骨折后 2.5 年内平均被吸收:首例人体应用的随访结果及羊模型的启示。
Clin Orthop Relat Res. 2024 Jan 1;482(1):184-197. doi: 10.1097/CORR.0000000000002799. Epub 2023 Aug 21.
6
Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study.第三代药物洗脱可吸收冠状动脉镁支架植入后的血管反应:BIOMAG-I 首例人体研究的血管内影像学分析。
EuroIntervention. 2024 Sep 16;20(18):e1173-e1183. doi: 10.4244/EIJ-D-24-00055.
7
A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial.生物心脏西罗莫司洗脱生物可吸收支架与依维莫司洗脱支架的随机对照研究:BIOHEART-II试验
JACC Cardiovasc Interv. 2025 Jan 13;18(1):15-27. doi: 10.1016/j.jcin.2024.09.043.
8
Predictors of target lesion failure after percutaneous coronary intervention with a drug-coated balloon for de novo lesions.药物涂层球囊经皮冠状动脉介入治疗治疗初发型病变后靶病变失败的预测因素。
EuroIntervention. 2024 Jul 1;20(13):e818-e825. doi: 10.4244/EIJ-D-23-01006.
9
Rotational Atherectomy, Lithotripsy, or Laser for Calcified Coronary Stenosis: One-Year Outcomes From the ROLLER COASTER-EPIC22 Trial.用于钙化冠状动脉狭窄的旋磨术、碎石术或激光治疗:ROLLER COASTER-EPIC22试验的一年结果
Catheter Cardiovasc Interv. 2025 Jul;106(1):702-710. doi: 10.1002/ccd.31529. Epub 2025 May 20.
10
Evaluation of post-dilatation on longitudinal stent deformation and postprocedural stent malapposition in the left main artery by optical coherence tomography (OCT): an in vitro study.光学相干断层成像术(OCT)评价左主干内支架纵向变形和术后支架贴壁不良:一项体外研究。
BMC Med Imaging. 2024 Mar 1;24(1):53. doi: 10.1186/s12880-024-01223-6.